{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:56:12Z","timestamp":1770918972949,"version":"3.50.1"},"reference-count":71,"publisher":"American Society for Microbiology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Numerous versions of human papillomavirus (HPV) therapeutic vaccines designed to treat individuals with established HPV infection, including those with cervical intraepithelial neoplasia (CIN), are in development because approved prophylactic vaccines are not effective once HPV infection is established. As human papillomavirus 16 (HPV-16) is the most commonly detected type worldwide, all versions of HPV therapeutic vaccines contain HPV-16, and some also contain HPV-18. While these two HPV types are responsible for approximately 70% of cervical cancer cases, there are other high-risk HPV types known to cause malignancy. Therefore, it would be of interest to assess whether these HPV therapeutic vaccines may confer cross-protection against other high-risk HPV types. Data available from a few clinical trials that enrolled subjects with CINs regardless of the HPV type(s) present demonstrated clinical responses, as measured by CIN regression, in subjects with both vaccine-matched and nonvaccine HPV types. The currently available evidence demonstrating cross-reactivity, epitope spreading, and<jats:italic>de novo<\/jats:italic>immune stimulation as possible mechanisms of cross-protection conferred by investigational HPV therapeutic vaccines is discussed.<\/jats:p>","DOI":"10.1128\/cvi.00149-15","type":"journal-article","created":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T02:01:01Z","timestamp":1430964061000},"page":"679-687","source":"Crossref","is-referenced-by-count":28,"title":["Cross-Reactivity, Epitope Spreading, and<i>De Novo<\/i>Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines"],"prefix":"10.1128","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0377-4613","authenticated-orcid":false,"given":"Mayumi","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Greenfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Moerman-Herzog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah N.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2015,5,6]]},"reference":[{"key":"key20180919073806_B1","article-title":"Cancer Facts & Figures 2014","volume-title":"American Cancer Society","author":"American Cancer Society","year":"2014"},{"key":"key20180919073806_B2","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jadohealth.2010.01.016","article-title":"Beyond cervical cancer: burden of other HPV-related cancers among men and women","volume":"46","year":"2010","journal-title":"J Adolesc Health"},{"key":"key20180919073806_B3","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.ypmed.2011.08.017","article-title":"Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies","volume":"53","year":"2011","journal-title":"Prev Med"},{"key":"key20180919073806_B4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/jnci\/djs491","article-title":"Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels","volume":"105","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"key20180919073806_B5","article-title":"Virus taxonomy","volume-title":"Seventh report of the International Committee for the Taxonomy of Viruses","year":"2002"},{"key":"key20180919073806_B6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.virol.2010.02.002","article-title":"Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments","volume":"401","year":"2010","journal-title":"Virology"},{"key":"key20180919073806_B7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years","volume":"199","year":"2009","journal-title":"J Infect Dis"},{"key":"key20180919073806_B8","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","year":"2006","journal-title":"Lancet"},{"key":"key20180919073806_B9","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1038\/bjc.2014.198","article-title":"Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV-16\/18 and closely related HPV types","volume":"110","year":"2014","journal-title":"Br J Cancer"},{"key":"key20180919073806_B10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"key20180919073806_B11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","year":"2009","journal-title":"Lancet"},{"key":"key20180919073806_B12","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years","volume":"199","year":"2009","journal-title":"J Infect Dis"},{"key":"key20180919073806_B13","first-page":"165","article-title":"Prophylactic HPV vaccines","volume":"28","year":"2007","journal-title":"Eur J Gynaecol Oncol"},{"key":"key20180919073806_B14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1471-2334-13-75","article-title":"Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands","volume":"13","year":"2013","journal-title":"BMC Infect Dis"},{"key":"key20180919073806_B15","doi-asserted-by":"publisher","first-page":"8585","DOI":"10.1016\/j.vaccine.2011.09.021","article-title":"Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera","volume":"29","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073806_B16","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.vaccine.2014.01.008","article-title":"Cross-neutralizing antibodies elicited by the Cervarix(R) human papillomavirus vaccine display a range of alpha-9 inter-type specificities","volume":"32","year":"2014","journal-title":"Vaccine"},{"key":"key20180919073806_B17","doi-asserted-by":"publisher","first-page":"e74797","DOI":"10.1371\/journal.pone.0074797","article-title":"Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"key20180919073806_B18","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/S0140-6736(96)90674-1","article-title":"A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"key20180919073806_B19","doi-asserted-by":"publisher","first-page":"169.e1-8","DOI":"10.1016\/j.ajog.2010.09.020","article-title":"Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy","volume":"204","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"key20180919073806_B20","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/sj.bjc.6605611","article-title":"Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia","volume":"102","year":"2010","journal-title":"Br J Cancer"},{"key":"key20180919073806_B21","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1016\/j.vaccine.2004.01.049","article-title":"Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16\/18 E6E7)","volume":"22","year":"2004","journal-title":"Vaccine"},{"key":"key20180919073806_B22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.vaccine.2004.05.013","article-title":"Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia","volume":"23","year":"2004","journal-title":"Vaccine"},{"key":"key20180919073806_B23","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"key":"key20180919073806_B24","first-page":"1028","article-title":"Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101","volume":"8","year":"2002","journal-title":"Clin Cancer Res"},{"key":"key20180919073806_B25","first-page":"3406","article-title":"A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive","volume":"6","year":"2000","journal-title":"Clin Cancer Res"},{"key":"key20180919073806_B26","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1067\/mob.2003.256","article-title":"Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA","volume":"188","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"key20180919073806_B27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/1078-0432.CCR-08-1725","article-title":"A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2\/3","volume":"15","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180919073806_B28","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/sj.cgt.7700937","article-title":"Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine","volume":"13","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"key20180919073806_B29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0090-8258(03)00083-0","article-title":"Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix","volume":"89","year":"2003","journal-title":"Gynecol Oncol"},{"key":"key20180919073806_B30","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1128\/JVI.02343-07","article-title":"Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial","volume":"82","year":"2008","journal-title":"J Virol"},{"key":"key20180919073806_B31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/01.AOG.0000110246.93627.17","article-title":"ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial","volume":"103","year":"2004","journal-title":"Obstet Gynecol"},{"key":"key20180919073806_B32","first-page":"206","article-title":"Efficacy and safety of RO5217990 treatment in patients with high grade cervical intraepithelial neoplasia (CIN2\/3)","year":"2012"},{"key":"key20180919073806_B33","article-title":"A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2\/3. Oncoimmunology, in press"},{"key":"key20180919073806_B34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.virol.2004.03.033","article-title":"Classification of papillomaviruses","volume":"324","year":"2004","journal-title":"Virology"},{"key":"key20180919073806_B35","first-page":"9","article-title":"Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone","volume":"6","year":"2006","journal-title":"Cancer Immun"},{"key":"key20180919073806_B36","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.3791\/3657","article-title":"Use of interferon-gamma enzyme-linked immunospot assay to characterize novel T-cell epitopes of human papillomavirus","volume":"2012","year":"2012","journal-title":"J Vis Exp"},{"key":"key20180919073806_B37","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1128\/CVI.00404-07","article-title":"Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable","volume":"15","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"key20180919073806_B38","doi-asserted-by":"publisher","first-page":"00018","DOI":"10.15406\/moji.2014.01.00018","article-title":"A human papillomavirus type 16 E6 52-62 CD4 T-cell epitope restricted by the HLA-DR11 molecule described in an epitope hotspot","volume":"1","year":"2014","journal-title":"MOJ Immunology"},{"key":"key20180919073806_B39","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1086\/656367","article-title":"Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-specific CD4+ memory T cell responses","volume":"202","year":"2010","journal-title":"J Infect Dis"},{"key":"key20180919073806_B40","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S1471-4906(02)00029-7","article-title":"Determinant spreading and tumor responses after peptide-based cancer immunotherapy","volume":"24","year":"2003","journal-title":"Trends Immunol"},{"key":"key20180919073806_B41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/imr.12091","article-title":"Virus infection, antiviral immunity, and autoimmunity","volume":"255","year":"2013","journal-title":"Immunol Rev"},{"key":"key20180919073806_B42","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1182\/blood.V96.9.3102","article-title":"Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells","volume":"96","year":"2000","journal-title":"Blood"},{"key":"key20180919073806_B43","first-page":"998","article-title":"Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma","volume":"9","year":"2003","journal-title":"Clin Cancer Res"},{"key":"key20180919073806_B44","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ijc.1323","article-title":"A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection","volume":"93","year":"2001","journal-title":"Int J Cancer"},{"key":"key20180919073806_B45","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/ijc.1420","article-title":"Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading","volume":"93","year":"2001","journal-title":"Int J Cancer"},{"key":"key20180919073806_B46","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/08820130009062294","article-title":"Dendritic cell\/peptide cancer vaccines: clinical responsiveness and epitope spreading","volume":"29","year":"2000","journal-title":"Immunol Invest"},{"key":"key20180919073806_B47","doi-asserted-by":"publisher","first-page":"670","DOI":"10.4161\/onci.20426","article-title":"Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001","volume":"1","year":"2012","journal-title":"Oncoimmunology"},{"key":"key20180919073806_B48","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1046\/j.1525-1470.2003.20318.x","article-title":"Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens","volume":"20","year":"2003","journal-title":"Pediatr Dermatol"},{"key":"key20180919073806_B49","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archderm.141.5.589","article-title":"Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial","volume":"141","year":"2005","journal-title":"Arch Dermatol"},{"key":"key20180919073806_B50","first-page":"263","article-title":"Intralesional immunotherapy for warts using a combination of skin test antigens: a safe and effective therapy","volume":"3","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"key20180919073806_B51","first-page":"451","article-title":"Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts","volume":"137","year":"2001","journal-title":"Arch Dermatol"},{"key":"key20180919073806_B52","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/archdermatol.2010.350","article-title":"Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts","volume":"146","year":"2010","journal-title":"Arch Dermatol"},{"key":"key20180919073806_B53","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1525-1470.2008.00630.x","article-title":"One-year experience with candida antigen immunotherapy for warts and molluscum","volume":"25","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"key20180919073806_B54","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1001\/archderm.136.10.1274","article-title":"Treatment of warts with Candida antigen injection","volume":"136","year":"2000","journal-title":"Arch Dermatol"},{"key":"key20180919073806_B55","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0092-1157(88)90027-3","article-title":"A novel Candida albicans skin test antigen: efficacy and safety in man","volume":"16","year":"1988","journal-title":"J Biol Stand"},{"key":"key20180919073806_B56","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.cyto.2013.11.002","article-title":"IL-12 secretion by Langerhans cells stimulated with Candida skin test reagent is mediated by dectin-1 in some healthy individuals","volume":"65","year":"2014","journal-title":"Cytokine"},{"key":"key20180919073806_B57","doi-asserted-by":"publisher","first-page":"5806","DOI":"10.1016\/j.vaccine.2013.10.014","article-title":"Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine","volume":"31","year":"2013","journal-title":"Vaccine"},{"key":"key20180919073806_B58","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1529-8019.2010.01388.x","article-title":"Intradermal injection of PPD as a novel approach of immunotherapy in anogenital warts in pregnant women","volume":"24","year":"2011","journal-title":"Dermatol Ther"},{"key":"key20180919073806_B59","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/ijc.23162","article-title":"Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element","volume":"122","year":"2008","journal-title":"Int J Cancer"},{"key":"key20180919073806_B60","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1099\/vir.0.82558-0","article-title":"Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women","volume":"88","year":"2007","journal-title":"J Gen Virol"},{"key":"key20180919073806_B61","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1119>3.0.CO;2-C","article-title":"Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes","volume":"91","year":"2001","journal-title":"Int J Cancer"},{"key":"key20180919073806_B62","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00262-008-0525-2","article-title":"A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells","volume":"58","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"key20180919073806_B63","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1447-0756.2003.00171.x","article-title":"Analysis of HLA-DRB1*0901-binding HPV-16 E7 helper T cell epitope","volume":"30","year":"2004","journal-title":"J Obstet Gynaecol Res"},{"key":"key20180919073806_B64","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1158\/1078-0432.CCR-06-2916","article-title":"HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions","volume":"13","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20180919073806_B65","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1128\/JVI.01768-06","article-title":"HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein","volume":"81","year":"2007","journal-title":"J Virol"},{"key":"key20180919073806_B66","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.4049\/jimmunol.154.11.5934","article-title":"Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides","volume":"154","year":"1995","journal-title":"J Immunol"},{"key":"key20180919073806_B67","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1128\/CDLI.11.5.889-896.2004","article-title":"Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins","volume":"11","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"key20180919073806_B68","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/1521-4141(2000)30:8<2281::AID-IMMU2281>3.0.CO;2-N","article-title":"Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif","volume":"30","year":"2000","journal-title":"Eur J Immunol"},{"key":"key20180919073806_B69","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ijc.20794","article-title":"Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer","volume":"114","year":"2005","journal-title":"Int J Cancer"},{"key":"key20180919073806_B70","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fimmu.2011.00075","article-title":"Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens","volume":"2","year":"2011","journal-title":"Front Immunol"},{"key":"key20180919073806_B71","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/cncr.26468","article-title":"Identification of novel immunogenic human leukocyte antigen-A 2402-binding epitopes of human papillomavirus type 16 E7 for immunotherapy against human cervical cancer","volume":"118","year":"2012","journal-title":"Cancer"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00149-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T04:39:26Z","timestamp":1691642366000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00149-15"}},"subtitle":[],"editor":[{"given":"C. J.","family":"Papasian","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,5,6]]},"references-count":71,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,6,23]]},"published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1128\/CVI.00149-15"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00149-15","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,6]]}}}